The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27117
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Competent (no legal guardian) males and females between the ages of 18 to 64
- Currently homeless or recent experience of homelessness, and symptoms of anxiety or depression
Exclusion Criteria:
- Younger than 18 and older than 65
- Patients who have attempted suicide with within the past twelve months or have active suicidal ideation will be excluded for possible safety concerns
- Self-reported illegal substance use in the past 30 days. Recent use of nicotine and alcohol will be allowed. However, those with current intoxication will be excluded
- History of a seizure disorder.
- Current history of autoimmune or endocrine disorder affecting the brain, unstable cardiac disease, history of skull fracture, or craniotomy
- Patients with pacemakers or internal electronic devices like deep brain stimulation and cochlear implants
- Women who are pregnant, nursing or planning to become pregnant
- Diagnosis of Schizophrenia or Schizoaffective disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Sham Device
Sham device
|
Sham device
|
|
Active Comparator: Intervention
CES device.
cranial electrotherapy stimulation device.
Alpha Stim device
|
cranial electrotherapy stimulation device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive Symptoms
Time Frame: 4 weeks
|
Hamilton Depression Rating Scale.
The Hamilton Rating Scale for Depression is a multiple item questionnaire used to provide an indication of depression and as a guide to evaluate recovery (Hedlund, 1979).
The questionnaire is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms.
A score of 0-7 is considered to be normal.
Scores of 20 or higher indicate moderate, severe, or very severe depression, and are usually required for entry into a clinical trial.
Assessment time is estimated at 20 minutes (Hamilton, 1960).
Higher values represent a worse outcome.
The HAM-D form lists 21 items, the scoring is based on the first 17.Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe.
Nine are scored from 0-2, with a total score range of 0-50.
|
4 weeks
|
|
Anxiety
Time Frame: 4 weeks
|
Hamilton Anxiety Rating Scale.
The Hamilton Anxiety Rating Scale (HAM-A) is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety (Hamilton, 1959; McDowell, Newell & & McDowell, 2006).
The scale consists of 14 items designed to assess the severity of a patient's anxiety.
Each of the 14 items contains a number of symptoms, and each group of symptoms is rated on a scale of zero to four, with four being the most severe (with a total score range of 0-56).
All of these scores are used to compute an overarching score that indicates a person's anxiety severity (Vaccarino, 2008).
A score of 17 or less indicates mild anxiety severity.
A score from 18 to 24 indicates mild to moderate anxiety severity.
Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity.
Higher values represent a worse outcome.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James Kimball, MD, Wake Forest Health Sciences
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00036461
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.